Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





DIPROPYLENE GLYCOL METHYL ETHER								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 34590-94-8; **Chemical Formula:** CH3OC3H6OC3H6OH
H.S. No. 1149
OSHA formerly had an 8-hour TWA limit of 100 ppm for dipropylene glycol methyl ether (DPGME), with a skin notation. The ACGIH recommends a TLV-TWA of 100 ppm and a TLV-STEL of 150 ppm, with a skin notation, for this colorless liquid with a mild, pleasant, ethereal odor and a bitter taste. OSHA proposed to retain the 8-hour permissible exposure limit of 100 ppm TWA, to add a 150-ppm STEL, and to retain the skin notation for dipropylene glycol methyl ether. NIOSH (Ex. 8-47, Table N1) concurs that these limits are appropriate, and the final rule establishes these limits.
Intact dogs receiving intravenous injections of DPGME exhibited central nervous system depression and died as a result of respiratory failure (Shideman and Procita 1951/Ex. 1-667). Rowe and associates (1954/Ex. 1-435) reported a single acute oral LD(50) for rats of 5.4 ml/kg. Even at the highest levels tested (not further specified), no single application of DPGME to the skin of rabbits was lethal, although some narcosis and transient weight loss did occur. However, a significant number of deaths occurred in a group of rabbits treated with 65 repeated dermal applications containing DPGME concentrations of 3 ml/kg or higher during a 90-day period. Four animal species, including the monkey, were exposed repeatedly to seven-hour daily inhalation exposures of between 300 and 400 ppm DPGME; the animals exhibited narcosis and changes in the lung and liver (Rowe, McCollister, Spencer et al. 1954/Ex. 1-435).
Humans inhaling DPGME concentrations of 300 to 400 ppm judged this level to be very disagreeable, but 100 ppm was tolerable and, in the opinion of the authors, was unlikely to produce organic injury (Rowe, McCollister, Spencer et al. 1954/Ex. 1-435). Patch tests on the skin of 250 human subjects produced neither irritation nor sensitization (ACGIH 1986/Ex. 1-3, p. 221). Humans exposed to DPGME vapor concentrations at levels between 50 to 2000 ppm experienced eye, nose, and throat irritation before the onset of CNS impairment, which occurred at 1000 ppm in one of two subjects (Stewart, Baretta, Dodd, and Torkelson 1970/Ex. 1-379).
NIOSH (Ex. 150, Comments on Dipropylene Glycol Monomethyl Ether) reported that it is developing a criteria document on the glycol ethers; NIOSH submitted recent toxicity data on DPGME, including the following: rats and mice inhaling concentrations of 50, 140, or 330 ppm DPGME six hours/day for nine days showed increased liver weights (at 50 and 140 ppm for the rat and at 330 ppm for the mouse), but no effects were observed when rats inhaled 15, 50, or 200 ppm DPGME six hours/day, five days/week for 13 weeks (Landry and Yano 1984, as cited in Ex. 150). NIOSH also reported results of a 1985 study by Miller et al. indicating that DPGME is metabolized via the same routes to the same types of metabolites – propylene glycol, and sulfate and glucuronide conjugates of DPGME – as previously identified for PGME (1-methoxy-2-propanol) (Miller, Hermann, Calhoun et al. 1985, as cited in Ex. 150). The Landry and Yano study (1984, as cited in Ex. 150) further indicated that at the concentrations tested, DPGME exerted no teratogenic or reproductive effects (NIOSH/Ex. 150, Comments on Dipropylene Glycol Monomethyl Ether).
The ARCO Chemical Company (Ex. 3-740) questioned the appropriateness of a skin notation for this substance. In response to ARCO, the Agency notes that DPGME, applied essentially according to the Draize method, is absorbed in sufficient quantities through rabbit skin to cause transient narcosis, although the absorption rate was not considered acutely dangerous (Patty’s Industrial Hygiene and Toxicology, 3rd rev. ed., Vol. 2C, p. 3990, Clayton and Clayton 1982). Topical administration of 10 mg/kg DPGME five times per week for 13 weeks to shaved rabbit skin caused six deaths among seven animals (Chemical Hazards of the Workplace, 2nd ed., p. 221, Proctor, Hughes, and Fischman, 1988). To date, there are no human data demonstrating that dermal contact with DPGME is without a significant adverse health risk; therefore, in accordance with the policy described in Section VI.C.18, OSHA finds that the available evidence does not meet the criterion for deleting an existing skin notation.
In the final rule, OSHA is retaining a PEL of 100 ppm TWA and adding a STEL of 150 ppm for dipropylene glycol methyl ether; the skin notation is retained. The Agency concludes that this combined limit will substantially reduce the significant risks of central nervous system effects and irritation, which constitute material health impairments, that exist when workers are exposed to DPGME for short periods above the 100-ppm PEL.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue